References
Schlimok G, Funke I, Bock B, Schweiber B, Witte J, Riethmullcr G. 1990. Epithelial tumour cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterisation and prognostic significance.J Clin Oncol 8: 831–837.
Lindemann F, Schlimok G, Dirshedl P, Witte J, Reithmuller G. 1992. Prognostic significance of mierometastatic tumour cells in bone marrow of colorectal cancer patients.Lancet 340: 685–689.
O’Sullivan GC, Collins JK, Kelly J, Morgan J, Madden M, Shanahan F. 1997. Micrometastases: marker of metastatic potential or evidence of residual disease. Gut 40: 512–515.
O’Sullivan GC, Collins JK, O’Brien F, Crowley B, Murphy K, Lee G, Shanahan F. 1995. Micrometastases in bone marrow of patients undergoing ‘curative’ surgery for gastrointestinal cancer.Gastroenterology 109: 1535–1540.
Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. 1991. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.J Clin Oncology 9: 1749–1756.
Braun S, Pantel K, Muller P et al. 2000. Cytokeratin positive cells in the bone marrow and survival of patients with Stage I, II or III Breast Cancer.N Engl J Med 342: 525–533.
Pantel K, Izbicki J, Passilick B, Angstwurm M, Haussinger K, Thetter O, Riethmuller G. 1996. Frequency and prognostic significance of micrometastatic tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases.Lancet 347: 646–553.
O’Sullivan G, Sheehan D, Clarke A, Stuart R, Kelly J, Kiely DM, Walsh T, Collins JK, Shanahan F. 1999. Micrometastases in esophagogastric cancer: High detection rate in resected rib segments.Gastroenterology 116: 543–548.
Uhr JW, Scheuermann RH, Street NE, Vitetta ES. 1997. Cancer dormancy: opportunities for new therapeutic approaches.Nature Medicine 3: 505–509.
Callaway MP, Briggs JC. The incidence of later recurrence (greater than 10 years): An analysis of 536 consecutive cases of cutaneous melanoma.Br J Plast Surg 1989; 42: 46–49.
Henderson JC, Harris JR, Kinne DW, Hellman S. Cancer of the breast. In Cancer: Principles and Practice of Oncology, 3rd edn (eds DeVita VJ, Jr, Hellman S and Rosenberg SA) 1197–1268 (Lippincott, Philadelphia, 1989).
Mintz B, Illmensee K. Normal genetically mosaic mice produced from malignant terato-carcinoma cells. 1975; Proc Natl Acad Sci USA 72: 3585–3589.
Richards B, Zhang H, Phear G and Meuth M. Conditional imitator phenotypes in hMSH2-deficient tumour cell lines. 1997;Science 277: 1523–1526.
Penn I. 1993. The effect of immunosuppression on pre-existing cancers. Transplantation 55: 742–747.
Pardoll DM. 1998. Cancer vaccines.Nature Medicine 4: 525–531.
O’Connell J, Bennett MW, O’Sullivan GC, Collins JK, Shanahan, F. 1999. FAS counter-attack — the best form of defense?Nature Medicine 5: 267–268.
O’Mahony A, O’Sullivan GC, O’Connell J, Cotter TG, Collins JK. An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage.J Immunol 1993; 151: 4847–56.
O’Sullivan GC, Corbett AR, Shanahan F, Collins JK. Regional immunosuppression in esophageal squamous cancer: Evidence from functional studies with matched lymph nodes.J Immunol 1996; 157: 4717–4720.
Nagata S, Golstein P. The FAS death factor.Science 1995; 267: 1449–1456.
Folkman J. Antiangiogenic Therapy: In Cancer: Principles and Practice of Oncology, 5th edition edited by Vincent DeVita Jr, Samuel Hellman, Stephen A Rosenberg, Lippincott-Raven Publishers, Philadelphia 1997 Chapter 64, 3075–3085
Folkman J. Tumour angiogenesis. Therapeutic implications.N Engl Med 285: 1182–1186, 1971.
Folkman J, Klagsburn M. Angiogcnic factors.Science 235: 442–447, 1987.
Holmgren L, O’Reilly MS, Folkman J. 1995. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.Nature Medicine 1: 149–153.
Bouck N. Angiogenesis: A mechanism by which oncogenes and tumour suppressor genes regulate tumorigenesis. Cancer Treat Res 63: 359–371, 1992.
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. 1994; Cell 79: 315–328.
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 88: 277–285.
O’Reilly MS, Holmgren L, Chen C, Folkman J. 1996. Angiostatin induces and sustains dormancy of human primary tumours in mice.Nature Medicine 2: 689–692.
McKenna HJ. 1999. Generating a T-cell immune response in vivo: can flt3-ligand-specific dendritic cells tip the balance? Cancer Immunology and Immunotherapy 48: 281–286.
Peron JP, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. 1998. FLT3-Ligand administration inhibits liver metastases: Role of NK cells.J Immunol 161: 6164–6170.
Levy R, Miller RA. Therapy of lymphoma directed at idiotypes. 1990;J Natl Cancer Inst Monqgr 10: 61–68.
Fendly BM et al. Characterisation of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. 1990; Cancer Res 50: 1550–1558.
Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumour effects in vivo. 1988; Oncogene 2: 387–394.
Riethmuller G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. 1994;Lancet 3: 1172–1174.
McNamara DA, Harney JH, Walsh TN, Redmond HP, Bouchier-Hayes DJ. Significance of angiogenesis in cancer therapy.Br J Surg 1998 Oct 85(10) 1a49.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O’Sullivan, G.C. A cure for cancer? Dealing with minimal residual disease. Ir J Med Sci 169, 13–16 (2000). https://doi.org/10.1007/BF03170474
Issue Date:
DOI: https://doi.org/10.1007/BF03170474